Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-101 in CD19+ Non-Hodgkin Lymphoma and Leukemia
NCT07518329Phase 1Recruiting
- Sponsor
- Arovella Therapeutics
- Start
- Oct 2026
- Primary completion
- Mar 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19 chimeric antigen receptor invariant natural killer T cells in non-Hodgkin lymphoma (NHL) and leukemia (5 arms), sponsored by Arovella Therapeutics. Primary endpoint: Safety and Tolerability at 2 years. Started Oct 2026; status: recruiting.
02
Drugs
anti-CD19 chimeric antigen receptor invariant natural killer T cells
03
Conditions
non-Hodgkin lymphoma (NHL)leukemia
Beyond the preview
Go deeper on NCT07518329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518329.